FDA Inspection 1223867 — Adimmune Corporation
The FDA completed an inspection of Adimmune Corporation on November 21, 2023 in Taichung City. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Biologics.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI) (VAI)
- End Date
- November 21, 2023
- Fiscal Year
- 2024
- Product Type
- Biologics
- Project Area
- Vaccines and Allergenic Products
- Location
- Taichung City (Taiwan)